Vilsmaier et al. reported that IL-1α is a candidate marker for the release of tumor cells and IL-1β, IL-12, sFlt1 and PlGF appears to be related to CTCs release in patients with BC16,17. The gene discussed is IL1A; the disease is neoplasm.